The TSX Venture Exchange has accepted for filing an investment agreement dated Oct. 10, 2018, between 10870277 Canada Inc., a wholly owned subsidiary of Organigram Holdings Inc., whereby the company may acquire a 25-per-cent interest in Alpha-Cannabis Pharma GMBH. Consideration is 1,616,667 euros and up to 875,000 euros in common shares of the company based on achievement of milestones.

For further details, please see the company's news release dated Oct. 17, 2018.